Clinical information on MIS-A patients
| . | MIS-A 1 . | MIS-A 2 . | MIS-A 3 . | MIS-A 4 . | MIS-A 5 . |
|---|---|---|---|---|---|
| Age | 33 | 50 | 23 | 38 | 35 |
| Gender | Male | Male | Female | Female | Female |
| Time from verified SARS-CoV-2 infection to admission | 7 wk | 3 wk | 6 wk | 0 day | 3 wk |
| Symptoms from MIS-A period | Persistent fever, dry cough, dyspnea, abdominal discomfort, diarrhea, respiratory and circulatory failure, and universal rash resembling erythema multiforme | Persistent fever, headache, sore throat, aching muscles and joints, abdominal pain, swollen lymph node on left side of neck, universal rash, and respiratory distress | High fever, myalgia, throat irritation, cough, expectoration, retrosternal chest pain, conjunctival injection, chapped lips, and bilateral lung consolidation | Persistent fever, sore throat, diarrhea, hypotension (80/60 mmHg), and myocarditis | High fever, abdominal pain, vomiting, myalgia (especially in lower extremities), labile blood pressure, and multiorgan failure |
| Treatment | IVIG, hydrocortisone, fluid resuscitation, vasopressor therapy, hemodialysis, ceftriaxone, clarithromycin, and respirator | IVIG, hydrocortisone, fluid resuscitation, Pip/Tazo, meropenem, clindamycin, and metronidazole | IVIG, methylprednisolone, acetylsalicylic acid, penicillin, and ciprofloxacin | IVIG, fluid resuscitation, and Pip/Tazo | Pip/Tazo and clindamycin |
| Time of blood sampling after first symptoms | 2 days | 14 days | 21 days | 5 days | 11 days |
| Treatment before blood sampling | Yes, during sampling | Yes, just prior to sampling | Yes, just prior to sampling | Yes, during sampling | Yes, just prior to sampling |
| COVID-19 vaccination status prior to MIS-A | No | No | No | No | Yes, vaccinated × 2 (before MIS period) |
| . | MIS-A 1 . | MIS-A 2 . | MIS-A 3 . | MIS-A 4 . | MIS-A 5 . |
|---|---|---|---|---|---|
| Age | 33 | 50 | 23 | 38 | 35 |
| Gender | Male | Male | Female | Female | Female |
| Time from verified SARS-CoV-2 infection to admission | 7 wk | 3 wk | 6 wk | 0 day | 3 wk |
| Symptoms from MIS-A period | Persistent fever, dry cough, dyspnea, abdominal discomfort, diarrhea, respiratory and circulatory failure, and universal rash resembling erythema multiforme | Persistent fever, headache, sore throat, aching muscles and joints, abdominal pain, swollen lymph node on left side of neck, universal rash, and respiratory distress | High fever, myalgia, throat irritation, cough, expectoration, retrosternal chest pain, conjunctival injection, chapped lips, and bilateral lung consolidation | Persistent fever, sore throat, diarrhea, hypotension (80/60 mmHg), and myocarditis | High fever, abdominal pain, vomiting, myalgia (especially in lower extremities), labile blood pressure, and multiorgan failure |
| Treatment | IVIG, hydrocortisone, fluid resuscitation, vasopressor therapy, hemodialysis, ceftriaxone, clarithromycin, and respirator | IVIG, hydrocortisone, fluid resuscitation, Pip/Tazo, meropenem, clindamycin, and metronidazole | IVIG, methylprednisolone, acetylsalicylic acid, penicillin, and ciprofloxacin | IVIG, fluid resuscitation, and Pip/Tazo | Pip/Tazo and clindamycin |
| Time of blood sampling after first symptoms | 2 days | 14 days | 21 days | 5 days | 11 days |
| Treatment before blood sampling | Yes, during sampling | Yes, just prior to sampling | Yes, just prior to sampling | Yes, during sampling | Yes, just prior to sampling |
| COVID-19 vaccination status prior to MIS-A | No | No | No | No | Yes, vaccinated × 2 (before MIS period) |
| . | MIS-A 6 . | MIS-A 7 . | MIS-A 8 . | MIS-A 9 . | MIS-A 10 . |
|---|---|---|---|---|---|
| Age | 46 | 32 | 39 | 18 | 44 |
| Gender | Male | Male | Female | Male | Male |
| Time from verified SARS-CoV-2 infection to admission | 7 wk | 5 wk | Unknown | 5 wk | 6 wk |
| Symptoms from MIS-A period | Fever, headache, adenomegaly, dysarthria, confusion, and refractory cardiogenic shock | Chest pain, syncope, complete heart block, and cardiogenic shock | Dyspnea and mixed distributive and cardiogenic shock | Fever, abdominal discomfort, diarrhea, universal rash, chest pain, and cardiogenic shock | Fever, diarrhea, abdominal pain, and cardiogenic shock |
| Treatment | Fluid therapy, vasopressor, inotropes, VA-ECMO, methylprednisolone, IVIG | External cardiac pacing, inotropes, methylprednisolone, IVIG | Fluid therapy, vasopressors, mechanical, ventilation renal replacement therapy, VA-ECMO, methylprednisolone, IVIG | Inotropes, VA-ECMO, methylprednisolone, IVIG | Fluid therapy, inotropes, vasopressors, mechanical ventilation, VA-ECMO, renal replacement therapy, methylprednisolone, IVIG |
| Time of blood sampling after first symptoms | 5 days | 6 days | 12 days | 7 days | 1 day |
| Treatment before blood sampling | Yes, just prior to sampling | Yes, just prior to sampling | Yes, just prior to sampling | Yes, just prior to sampling | No |
| COVID-19 vaccination status prior to MIS-A | Yes, 3 doses (last dose 10 mo prior) | Unknown | Yes, 2 doses | Unknown | No |
| . | MIS-A 6 . | MIS-A 7 . | MIS-A 8 . | MIS-A 9 . | MIS-A 10 . |
|---|---|---|---|---|---|
| Age | 46 | 32 | 39 | 18 | 44 |
| Gender | Male | Male | Female | Male | Male |
| Time from verified SARS-CoV-2 infection to admission | 7 wk | 5 wk | Unknown | 5 wk | 6 wk |
| Symptoms from MIS-A period | Fever, headache, adenomegaly, dysarthria, confusion, and refractory cardiogenic shock | Chest pain, syncope, complete heart block, and cardiogenic shock | Dyspnea and mixed distributive and cardiogenic shock | Fever, abdominal discomfort, diarrhea, universal rash, chest pain, and cardiogenic shock | Fever, diarrhea, abdominal pain, and cardiogenic shock |
| Treatment | Fluid therapy, vasopressor, inotropes, VA-ECMO, methylprednisolone, IVIG | External cardiac pacing, inotropes, methylprednisolone, IVIG | Fluid therapy, vasopressors, mechanical, ventilation renal replacement therapy, VA-ECMO, methylprednisolone, IVIG | Inotropes, VA-ECMO, methylprednisolone, IVIG | Fluid therapy, inotropes, vasopressors, mechanical ventilation, VA-ECMO, renal replacement therapy, methylprednisolone, IVIG |
| Time of blood sampling after first symptoms | 5 days | 6 days | 12 days | 7 days | 1 day |
| Treatment before blood sampling | Yes, just prior to sampling | Yes, just prior to sampling | Yes, just prior to sampling | Yes, just prior to sampling | No |
| COVID-19 vaccination status prior to MIS-A | Yes, 3 doses (last dose 10 mo prior) | Unknown | Yes, 2 doses | Unknown | No |
| . | MIS-A 11 . | MIS-A 12 . | MIS-A 13 . | MIS-A 14 . | MIS-A 15 . |
|---|---|---|---|---|---|
| Age | 22 | 33 | 25 | 25 | 19 |
| Gender | Female | Male | Male | Female | Male |
| Time from verified SARS-CoV-2 infection to admission | 3 wk | 4 wk | 7 days | Unknown | 4 wk |
| Symptoms from MIS-A period | Fever, cough, sore throat, headache, diarrhea, conjunctivitis, and cardiogenic shock | Fever, adenomegaly, sore throat, and cardiogenic shock | Sore throat, fever, and myocarditis | Fever, sore throat, chest pain, and cardiogenic shock | Diarrhea, myalgia, dyspnea, and cardiogenic shock |
| Treatment | Fluid therapy, inotropes, vasopressors, methylprednisolone, IVIG | Fluid therapy, inotropes, vasopressors, methylprednisolone, IVIG | Inotropes, methylprednisolone, IVIG | Inotropes, vasopressors, VA-ECMO, methylprednisolone, IVIG | Inotropes, vasopressors, VA-ECMO, methylprednisolone, IVIG |
| Time of blood sampling after first symptoms | 9 days | 3 days | 7 days | 3 days | 5 days |
| Treatment before blood sampling | Yes, just prior to sampling | Yes, just prior to sampling | Yes, just prior to sampling | No | Yes, just prior to sampling |
| COVID-19 vaccination status prior to MIS-A | No | Unknown | No | No | No |
| . | MIS-A 11 . | MIS-A 12 . | MIS-A 13 . | MIS-A 14 . | MIS-A 15 . |
|---|---|---|---|---|---|
| Age | 22 | 33 | 25 | 25 | 19 |
| Gender | Female | Male | Male | Female | Male |
| Time from verified SARS-CoV-2 infection to admission | 3 wk | 4 wk | 7 days | Unknown | 4 wk |
| Symptoms from MIS-A period | Fever, cough, sore throat, headache, diarrhea, conjunctivitis, and cardiogenic shock | Fever, adenomegaly, sore throat, and cardiogenic shock | Sore throat, fever, and myocarditis | Fever, sore throat, chest pain, and cardiogenic shock | Diarrhea, myalgia, dyspnea, and cardiogenic shock |
| Treatment | Fluid therapy, inotropes, vasopressors, methylprednisolone, IVIG | Fluid therapy, inotropes, vasopressors, methylprednisolone, IVIG | Inotropes, methylprednisolone, IVIG | Inotropes, vasopressors, VA-ECMO, methylprednisolone, IVIG | Inotropes, vasopressors, VA-ECMO, methylprednisolone, IVIG |
| Time of blood sampling after first symptoms | 9 days | 3 days | 7 days | 3 days | 5 days |
| Treatment before blood sampling | Yes, just prior to sampling | Yes, just prior to sampling | Yes, just prior to sampling | No | Yes, just prior to sampling |
| COVID-19 vaccination status prior to MIS-A | No | Unknown | No | No | No |
| . | MIS-A 16 . |
|---|---|
| Age | 16 |
| Gender | Male |
| Time from verified SARS-CoV-2 infection to admission | Unknown |
| Symptoms from MIS-A period | Chest pain, headache, fever, abdominal discomfort, and cardiogenic shock |
| Treatment | Inotropes, methylprednisolone |
| Time of blood sampling after first symptoms | 2 days |
| Treatment before blood sampling | No |
| COVID-19 vaccination status prior to MIS-A | Unknown |
| . | MIS-A 16 . |
|---|---|
| Age | 16 |
| Gender | Male |
| Time from verified SARS-CoV-2 infection to admission | Unknown |
| Symptoms from MIS-A period | Chest pain, headache, fever, abdominal discomfort, and cardiogenic shock |
| Treatment | Inotropes, methylprednisolone |
| Time of blood sampling after first symptoms | 2 days |
| Treatment before blood sampling | No |
| COVID-19 vaccination status prior to MIS-A | Unknown |
Pip/Tazo, piperacillin/tazobactam; VA-ECMO, venoarterial extracorporeal membrane oxygenation.